Navigation Links
Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
Date:5/15/2008

The REACH Registry reveals that 70% of deaths in the stable stroke

population were due to a cardiovascular event other than stroke

NICE, France, May 15 /PRNewswire/ -- New two-year data from the REACH Registry presented at the European Stroke Congress, highlight that among those who die after a stroke the vast majority (73%) will die from nonstroke cardiovascular (CV) events. The overall death rate is 4.45%, with 3.23% of these CV deaths from a nonstroke event.

The two-year data from the REACH Registry demonstrate that the risk of secondary ischemic events (including CV death) is very high in patients with previous stroke and/or TIA.

The REACH Registry has demonstrated that there is a high prevalence of atherothrombosis in more than one vascular bed: one-quarter of patients with coronary artery disease (CAD), two-fifths of patients with cerebrovascular disease (CVD) and three-fifths of patients with peripheral artery disease (PAD) also have atherothrombosis in other arterial locations. REACH Registry data also highlight the undertreatment of patients with CVD in the real-world setting. Improving ischemic risk management in these patients is required to prevent hospitalization and death.

Approximately 28% of patients in the REACH Registry have diagnosed CVD at baseline. About 40% of patients with CVD have polyvascular disease. Of the total CVD population at baseline: 71% suffered a prior stroke; 51% had a prior TIA; and, 20% had both.

Two-year data in the CVD population show high event rates for non-fatal stroke (5.9%). The risk of stroke, MI and CV death at two years was 11.5% for the total CVD population. Patients with a history of CVD are at considerable risk of major adverse cardiac events (MACE) and hospitalizations (>20% at two years).

"CVD patients are at high risk of recurrent stroke and other atherothrombotic events. Moreover the REACH Registry has shown that most of these stable stroke patients are a
'/>"/>

SOURCE REACH Registry
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Biomatricas RNAstable(TM) Stabilizes RNA at Room Temperature
3. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
4. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
10. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2
... Stockholders Approve Board Authority to Implement Reverse Stock Split and ... of Total Shares and Authorized Shares, NEW HAVEN, Conn., ... that a Special Meeting of,Stockholders was held at the Omni ... At the meeting, shareholders voted to approve amendments to the,Company,s ...
... - For Full Year 2007, Strong Operating Earnings and Tax Benefits Drive ... and Product Sales Both Grow 14% -, - In 2008, Gen-Probe Expects ... Driving Anticipated EPS of ... GPRO ) today reported strong financial results for the fourth,quarter and ...
... DENVER, Feb. 13 Rocky Mountain Biosystems, ... announced receipt of a,grant award of approximately ... of Allergy and Infectious Diseases at the ... Self-Administered Vaccination Electromechanical,(SAVE) technology for influenza vaccination. ...
Cached Biology Technology:Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 2Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 4Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 5Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 6Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 7Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 8Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 9Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 10Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 11Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 12Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 13Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 14Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 15Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 16NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza 2
(Date:7/11/2014)... Institute of Standards and Technology (NIST) need a ... they often prove that necessity is truly the ... for M. Lorna De Leoz and Stephen Stein, ... glycomics. Glycomics is the study of the abundant, ... to proteins and lipids and influence cellular processes, ...
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... and the Manchester Metropolitan University have carried out the ... amber more than 30 millions years ago. , The ... the Dominican (Caribbean) regions has revealed new insights into ... period. , It is the first time ancient spiders ...
... at the National Institute of Allergy and Infectious Disease ... (NIH), have identified a critical human cell surface molecule ... virus that causes Kaposi's sarcoma and certain forms of ... HIV/AIDS, and it typically manifests as multiple purple-hued skin ...
... the amino acid supplement L-arginine following a heart attack ... may be associated with an increased risk of death, ... of JAMA. , L-arginine is a widely available dietary ... with hypertension, angina, heart failure and sexual dysfunction, according ...
Cached Biology News:Amber reveals ecology of 30 million year old spiders 2Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 2Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 3Little known DNA repair enzyme may be a tumor suppressor gene 2
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: